I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

And it’s never a bad time to re-read some of the team’s excellent, award-winning coverage on the company: Last week, key ...